Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2024

Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2024

DelveInsight’s, “Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Progressive Multifocal Leukoencephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Progressive Multifocal Leukoencephalopathy Understanding

Progressive Multifocal Leukoencephalopathy (PML): Overview

PML is a rare disease that causes rapidly fatal brain infection. It occurs as a side effect of some medications used to treat multiple sclerosis and other autoimmune diseases as well as in patients with HIV and certain cancers of the blood and lymph. PML is caused by a human polyomavirus, the John Cunningham virus (JC virus), which resides in an inactive form in the kidney and bone marrow of more than 60% of adults. PML develops when the inactive form of the JC virus becomes activated in patients, due to chronic or drug-induced immune suppression, whereupon the virus migrates into the brain and causes irreversible brain damage, a debilitating loss of cognitive and motor function, and likely death. There is currently no approved treatment for PML.

""Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Progressive Multifocal Leukoencephalopathy pipeline landscape is provided which includes the disease overview and Progressive Multifocal Leukoencephalopathy treatment guidelines. The assessment part of the report embraces, in depth Progressive Multifocal Leukoencephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Progressive Multifocal Leukoencephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Multifocal Leukoencephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Progressive Multifocal Leukoencephalopathy.

Progressive Multifocal Leukoencephalopathy Emerging Drugs Chapters

This segment of the Progressive Multifocal Leukoencephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Progressive Multifocal Leukoencephalopathy Emerging Drugs

• NT-I7: NeoImmuneTech

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

• IkT-01427: Inhibikase Therapeutics

IkT-01427 is an oral, brain-penetrant medication for systemic administration that is designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body. IkT-01427 is a new molecular entity that was developed with the company’s RAMP™ technology.

Further product details are provided in the report……..

Progressive Multifocal Leukoencephalopathy: Therapeutic Assessment

This segment of the report provides insights about the different Progressive Multifocal Leukoencephalopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Progressive Multifocal Leukoencephalopathy

There are approx. 3+ key companies which are developing the therapies for Progressive Multifocal Leukoencephalopathy. The companies which have their Progressive Multifocal Leukoencephalopathy drug candidates in the most advanced stage, i.e. phase I include, NeoImmuneTech.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Progressive Multifocal Leukoencephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Progressive Multifocal Leukoencephalopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Progressive Multifocal Leukoencephalopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Progressive Multifocal Leukoencephalopathy drugs.

Progressive Multifocal Leukoencephalopathy Report Insights

• Progressive Multifocal Leukoencephalopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Progressive Multifocal Leukoencephalopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Progressive Multifocal Leukoencephalopathy drugs?
• How many Progressive Multifocal Leukoencephalopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Multifocal Leukoencephalopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Progressive Multifocal Leukoencephalopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Progressive Multifocal Leukoencephalopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Inhibikase Therapeutics
• Neurimmune
• Excision BioTherapeutics
• I-MAB Biopharma

Key Products

• IkT-01427
• NI307
• EBT 103
• Efineptakin alfa